Arecor Therapeutics (FRA:6UI) YoY EBITDA Growth: 1,783.33% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6UI Arecor Therapeutics PLC FRA:6UI
39 GF Score
Price €0.65
GF Value €0.42
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics YoY EBITDA Growth?

Arecor Therapeutics FRA:6UI 39 YoY EBITDA Growth is 1,783.33% as of Dec. 2025. GuruFocus rates FRA:6UI with a GF Score™ of 39/100 and a GF Value™ of €0.42. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Arecor Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 1,783.33%.

Arecor Therapeutics's EBITDA per Share for the six months ended in Dec. 2025 was €0.10.

Arecor Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Arecor Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics YoY EBITDA Growth Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only -165.38 -15.94 20.50 46.54 120.59

Arecor Therapeutics Semi-Annual Data
May17 May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.63 -4.14 96.00 57.39 1,783.33
FRA:6UI
39GF Score
Arecor Therapeutics PLC FRA:6UI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Arecor Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.035--0.17)/ | -0.17 |
=120.59 %

Arecor Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.101--0.006)/ | -0.006 |
=1,783.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 1,783.33% mean?
Arecor Therapeutics (FRA:6UI) has a YoY EBITDA Growth of 1,783.33% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' YoY EBITDA Growth too high?
Arecor Therapeutics' current YoY EBITDA Growth is 1,783.33%. Overall, Arecor Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' YoY EBITDA Growth compare to VRTX and REGN?
Arecor Therapeutics' YoY EBITDA Growth of 1,783.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Arecor Therapeutics and its competitors. Arecor Therapeutics's current YoY EBITDA Growth is 1,783.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current YoY EBITDA Growth of 1,783.33%. The stock's GF Value™ is €0.42, compared to a current price of €0.65 — trading 54.8% above its estimated fair value. The current YoY EBITDA Growth is 1,783.33%. Arecor Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current YoY EBITDA Growth is 1,783.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.65 is trading 54.8% above its estimated GF Value™ of €0.42.

Key valuation signals for FRA:6UI:

  • YoY EBITDA Growth: 1,783.33%
  • GF Value™: €0.42 vs. price of €0.65 (54.8% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges AREC:UK6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
39GF Score

Get the complete analysis for FRA:6UI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.65
Price
€0.42
GF Value